复智散治疗老年性痴呆的临床疗效观察  

The efficacy of fuzhisan in patients with Alzheimer's disease

作　　者：刚宝芝[1] 王德生[1] 王春利[1] 汤颖[1] 张艳[1] 杨志杰[2] 马铎[2] 

机构地区：[1]哈尔滨医科大学第一临床医学院神经内科,黑龙江哈尔滨150001 [2]哈尔滨医科大学第一临床医学院核医学科,黑龙江哈尔滨150001

出　　处：《中风与神经疾病杂志》2005年第6期527-529,共3页Journal of Apoplexy and Nervous Diseases

基　　金：黑龙江省自然基金重点项目(项目号ZJY03-5)

摘　　要：目的探讨中药复智散治疗老年性痴呆(AD)的临床疗效。方法入选确诊的54例AD患者,随机分为复智散治疗组和安理申治疗组,单盲法分别规范治疗40d。治疗前后用MMSE、ADAS量表评估各组临床疗效, 行头部SPECT评价脑血流灌注状况,同时观察不良反应。结果复智散组的MMSE总分、ADAS-cog评分以及 ADAS-noncog评分均有显著改善。头部SPECT结果显示复智散能广泛改善AD患者的脑区血流灌注,单项临床症状的改善与局部脑区血流灌注呈显著正相关。结论复智散是一个治疗AD安全有效的中药。Objective To assess the efficacy of fuzhisan,a Chinese herb,in treatment of Alzheimer＇s disease （AD）. Methods A 40-day randomized,single-blind controlled clinical trial was conducted in 54 patients with AD. Patients were randomly assigned to fuzhisan group and donepezil group. The scales of MMSE ,ADAS were used to assess the effects and BIP were investigated by SPECT. The adverse effects were also observed. Result Compared with donepezil group,fuzhisan group had a significantly better outcome on language,orientation and ADAS-noncog （P〈0. 05） ,except on memory（P〉0. 05）. SPECT evaluation before and after treatment showed an increase in RPI in almost all investigated regions of the brain in fuzhisan group. The improving of RPI was better in frontal ,parietal and cingulated gyrus regions with fuzhisan group, but better in temporal ahd hippocampus regions in donepezil group. RPI positively correlated with the symptomatic improvement. Conclusion Fuzhisan is safe and effective prescription of Chinese herb for AD.

关 键 词：AD 复智散 安理申 SPECT 脑血流灌注 

分 类 号：R742[医药卫生—神经病学与精神病学]